Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, placebo-controlled, 3-phase crossover study of assessing effect of posaconazole on ibrutinib pharmacokinetics

Next Previous
Trial Profile

A randomized, placebo-controlled, 3-phase crossover study of assessing effect of posaconazole on ibrutinib pharmacokinetics

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Posaconazole
  • Indications Acute myeloid leukaemia; B-cell leukaemia; B-cell lymphoma; Chronic myeloid leukaemia; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastrointestinal cancer; Graft-versus-host disease; Hairy cell leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; SARS-CoV-2 acute respiratory disease; Solid tumours; Squamous cell cancer; T-cell prolymphocytic leukaemia; Urogenital cancer; Waldenstrom's macroglobulinaemia
  • Focus Pharmacokinetics

Most Recent Events

  • 27 Oct 2023 New trial record
  • 23 Oct 2023 Janne Backman is principal investigator of this trial, according to results published in the British Journal of Clinical Pharmacology.
  • 23 Oct 2023 Results assessing effect of the CYP3A4-inhibiting antifungal posaconazole on ibrutinib pharmacokinetics published in the British Journal of Clinical Pharmacology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top